BIVI Stock Summary and Trading Ideas (Biovie | NASDAQ:BIVI)

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Biovie trades on the NASDAQ stock market under the symbol BIVI.

As of January 12, 2026, BIVI stock price declined to $1.26 with 68,119 million shares trading.

BIVI has a beta of 1.12, meaning it tends to be more sensitive to market movements. BIVI has a correlation of 0.02 to the broad based SPY ETF.

BIVI has a market cap of $9.49 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BIVI traded as high as $1,138.99 and as low as $1.10.

The top ETF exchange traded funds that BIVI belongs to (by Net Assets): VTI, VXF.

BIVI has underperformed the market in the last year with a return of -94.3%, while the SPY ETF gained +21.0%. In the last 3 month period, BIVI fell short of the market, returning -31.1%, while SPY returned +6.8%. However, in the most recent 2 weeks BIVI has outperformed the stock market by returning +2.4%, while SPY returned +1.1%.

BIVI support price is $1.20 and resistance is $1.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIVI shares will trade within this expected range on the day.